Net present value cost analysis for treating retinitis pigmentosa
Novel gene therapies for RP likely offset significant government costs toward disability payments; these savings may be even greater when administered during adolescence.
Authors
- Jason Fehr
- Dejan Milentijevic (ORCID: https://orcid.org/0000-0003-2159-0049)
- S. Puri (ORCID: https://orcid.org/0000-0001-7669-3198)
- Sarah S Hellems
- Salina Yip
Institutions
- Johnson & Johnson (United States) (US)
- Optum (United States) (US)
- Janssen (United States) (US)
- Janssen Scientific Affairs (United States)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1080/13696998.2025.2559533
- Primary Topic
- Retinal Development and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00